GENERAL COMMENTS
The manuscript is fine as far as it goes. However, the basic assumption of the manuscript regarding desirable serum 25OHD concentrations is not consistent with international standards for optimal health.
From the text: "Based on the available results, a serum 25-hydroxyvitamin D (25-OH-D) test result <50 nmol/l (<20 ng/ml) was considered as the threshold for vitamin D insufficiency, while a value <30 nmol/l (<12 ng/ml) was considered as deficiency, following Australian and international guidelines.2 3 9 11" Comment: The international standard for optimal health is at least 75 nmol/l: "The bone-centric guidelines recommend a target 25(OH)D concentration of 20ng/mL (50nmol/L), and age-dependent daily vitamin D doses of 400-800IU. The guidelines focused on pleiotropic effects of vitamin D recommend a target 25(OH)D concentration of 30ng/mL (75nmol/L), and age-, body weight-, disease-status, and ethnicity dependent vitamin D doses ranging between 400 and 2000IU/day." as reported in Pludowski et al., 2018 (Ref. 2 in the manuscript).
The problem in Australia is that the majority of the population has pale skin, ideally suited for high latitudes of the UK. As a result, health officials and researchers are afraid to recommend higher 25(OH)D concentrations since that would encourage people to spend more time in the sun, increasing the risk of skin cancer and melanoma.
Vitamin D--an emerging issue in skin cancer control. Implications for public health practice based on the Australian experience.
Thus, in the opinion of the reviewer, if Australia adopted higher serum 25OHD concentrations and urged people to take 1000-2000 IU/d vitamin D3, disease rates would be reduced and serum 25OHD testing could be dialed back. I suggest that the authors discuss the emerging evidence for health benefits of higher 25OHD concentrations and the alternative to testing of recommending vitamin D supplementation (or sensible sun exposure). 
REVIEWER

GENERAL COMMENTS
This is an interesting article which provides not only data regarding the evolution of the number of vitamin D testing over time and particularly before and after the introduction of new Medicare criteria for rebates in general practice in Australia but also data regarding the appropriateness of the prescription, the relationship between testing prescribing practices, and the socio-economical level of the practices location. Few comments/ corrections have to be made. In the introduction a number of factors that increase the risk of vitamin insufficiency or deficiency are missing such as low socioeconomic level, obesity, covering cloths… and should be mentioned. Page 5, line 42, the number: 3.5/1000 individuals is probably a mistake as it is thereafter indicated that there was a considerable reduction to 14.4/1000 individuals.
The crude numbers of testing should be provided along with the number of testing/1000 individuals.
As the study population is not a representative sample of the general population (and the participating practitioners are also not representative regarding their behaviors), it would be appropriate to check whether the evolution of the number and proportion of vitamin D testing within the MedicineInsight had the same evolution as in the national database. The manuscript is fine as far as it goes. However, the basic assumption of the manuscript regarding desirable serum 25OHD concentrations is not consistent with international standards for optimal health. R: We appreciate all reviewer's contributions and time spent reading our manuscript. We believe most suggestions have been incorporated into the paper. We would also like to emphasize this paper does not aim to assess what is the best cut-off point for defining vitamin D deficiency, but to describe patterns of vitamin D testing and deficiency detection based on current Australian guidelines and suggested cut-off points recommended by the Medicare Benefits Schedule (MBS) to be used by general practitioners when assessing their patients.
From the text: "Based on the available results, a serum 25-hydroxyvitamin D (25-OH-D) test result <50 nmol/l (<20 ng/ml) was considered as the threshold for vitamin D insufficiency, while a value <30 nmol/l (<12 ng/ml) was considered as deficiency, following Australian and international guidelines. The problem in Australia is that the majority of the population has pale skin, ideally suited for high latitudes of the UK. As a result, health officials and researchers are afraid to recommend higher 25(OH)D concentrations since that would encourage people to spend more time in the sun, increasing the risk of skin cancer and melanoma.
• Vitamin D--an emerging issue in skin cancer control. Implications for public health practice based on the Australian experience. Sinclair C. Recent Results Cancer Res. 2007; 174:197- Thus, in the opinion of the reviewer, if Australia adopted higher serum 25OHD concentrations and urged people to take 1000-2000 IU/d vitamin D3, disease rates would be reduced and serum 25OHD testing could be dialed back. I suggest that the authors discuss the emerging evidence for health benefits of higher 25OHD concentrations and the alternative to testing of recommending vitamin D supplementation (or sensible sun exposure). R: We appreciate the suggestion and the list of references provided by the reviewer. Although this paper did not aim to investigate the best threshold for defining vitamin D deficiency, we have accepted the recommendation and this aspect is now commented in the discussion section. This is an interesting article which provides not only data regarding the evolution of the number of vitamin D testing over time and particularly before and after the introduction of new Medicare criteria for rebates in general practice in Australia but also data regarding the appropriateness of the prescription, the relationship between testing prescribing practices, and the socio-economical level of the practices location. R: We appreciate the reviewer's perspective on this paper.
In the introduction a number of factors that increase the risk of vitamin insufficiency or deficiency are missing such as low socio-economic level, obesity, covering cloths… and should be mentioned. Page 5, line 42, the number: 3.5/1000 individuals is probably a mistake as it is thereafter indicated that there was a considerable reduction to 14.4/1000 individuals. R: We apologise for this mistake. The real number is 36.5/1000 individuals. The number has been corrected.
The crude numbers of testing should be provided along with the number of testing/1000 individuals. R: We appreciate this suggestion but decided to keep the tables in their current format including only the testings/1000 consults. Crude numbers (absolute data) on the total number of tests does not allow comparability across categories and would pollute the table, making it harder for readers to follow the table. Other papers published in BMJ Open and other journals use a similar pattern of data presentation. However, if the editor considers that the requested information is relevant for the paper, we can provide it as a supplementary document.
As the study population is not a representative sample of the general population (and the participating practitioners are also not representative regarding their behaviors), it would be appropriate to check whether the evolution of the number and proportion of vitamin D testing within the MedicineInsight had the same evolution as in the national database. R: As stated in the discussion section, although individuals included in the MedicineInsight database are not a random sample of the whole population in Australia, their distribution according to gender, age, rurality and socioeconomic position resembles data from the last Australian census. There is no a national database to compare our results, or a more recent national study that would allow us to compare these trends (see Page 7, Lines 24-29, and references 18, 19, and 35). In any case, this issue has been also included as a possible limitation of the study (Page 18, Lines 58-59).
Page 9 line 40-44 this decision (threshold for abnormality) should be justified. R: Suggestion accepted. We used this strategy to reduce the number of false positives and improve specificity in the diagnosis of individuals with altered laboratory results (Page 10, Isn't the list of medication that might decrease the 25(OH)D level provided in the criteria #5 of the MBS clinical criteria? R: Although a report published in 2014 by the Australian Department of Health included some of these drugs (Australian Government, Department of Health. MBS reviews, Vitamin D testing report. www.health.gov.au/internet/.../Vitamin%20D%20testing%20Review%20Report.pdf), the clinical criteria published by the MBS did not include a detailed list (https://www.nps.org.au/radar/articles/mbs-item-number-changes-for-vitamin-b12-folate-and-vitamind-tests), and only anticonvulsants are mentioned as an example. We have amended the text in the methods section (Page 10, Lines 22-24).
Page 11 line 29: what means p25-p75 2.0;9.0? R: It represents the interquartile range. We have amended the text to substitute the term (Page 11, Line 52).
Page 14 line 33: regarding countries that have adopted strategies, there should be references of the published data to facilitate comparisons. R: Suggestion accepted. Although these studies did not investigate the effect at a national level, we have now included the impact of such kind of strategies identified in these studies (Page 15, .
